Eton Pharmaceuticals (NASDAQ:ETON) & ABVC BioPharma (NASDAQ:ABVC) Head-To-Head Contrast

Eton Pharmaceuticals (NASDAQ:ETON) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Profitability

This table compares Eton Pharmaceuticals and ABVC BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
ABVC BioPharma	N/A	-47.68%	-30.97%

Volatility & Risk

Eton Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Institutional and Insider Ownership

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Eton Pharmaceuticals and ABVC BioPharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0	1	4	1	3.00
ABVC BioPharma	1	0	0	0	1.00

Eton Pharmaceuticals currently has a consensus target price of $71.50, suggesting a potential upside of 43.00%. Given Eton Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Eton Pharmaceuticals is more favorable than ABVC BioPharma.

Valuation & Earnings

This table compares Eton Pharmaceuticals and ABVC BioPharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95 million	17.87	-$4.60 million	$0.38	131.58
ABVC BioPharma	$510,000.00	54.43	-$7.91 million	($0.30)	-3.47

Eton Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eton Pharmaceuticals beats ABVC BioPharma on 13 of the 15 factors compared between the two stocks.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.